Evidence map›Paper›PMID 34745940›Full record

ArticleFrontiers in oncology2021

LncRNA LGALS8-AS1 Promotes Breast Cancer Metastasis Through miR-125b-5p/SOX12 Feedback Regulatory Network.

Duanyang Zhai, Tianfu Li, Runyi Ye, Jiong Bi, Xiaying Kuang, Yawei Shi, Nan Shao, Ying Lin

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. A Comprehensive Understanding ofCurrent issues in molecular biology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. siRNA and targeted delivery systems in breast cancer therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  6. [miR-125b-5p inhibits proliferation and migration of osteosarcoma cells by negatively regulating RAB3D expression].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Duanyang ZhaiBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Tianfu LiBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Runyi YeBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jiong BiLaboratory of Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Xiaying KuangBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yawei ShiBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Nan ShaoBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ying LinBreast Disease Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastasis is a major factor weakening the long-term survival of breast cancer patients. Increasing evidence revealed that long non-coding RNAs (lncRNAs) were involved in the occurrence and development of breast cancer. In this study, we aimed to investigate the role of LGALS8-AS1 in the metastatic progression of breast cancer cells and its potential mechanisms.

resultsThe lncRNA LGALS8-AS1 was highly expressed in breast cancer and associated with poor survival. LGALS8-AS1 functioned as an oncogenic lncRNA that promoted the metastasis of breast cancer both

conclusionThis study manifested a novel mechanism of LGALS8-AS1 facilitating the metastasis of breast cancer. The LGALS8-AS1/miR-125b-5p/SOX12 reciprocal regulatory loop dyscrasia promoted the migration and invasion of breast cancer cells. This signaling axis could be applicable to the design of novel therapeutic strategies against this malignancy.

Indexed as

EMTfeedbackLGALS8-AS1metastasismiR-125b-5pSOX12

Identifiers

PMID34745940
PMCPMC8570098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.